Initial Patent Filing

Initial Patent Filing (Italy, June 30, 2023):
- Theranib filed its first patent, titled “Medicinal compound for the inhibition of aldehyde dehydrogenase subtype 1A (ALDH1A3)”.
- The patent protects the intellectual property surrounding VE3, a novel small molecule with unprecedented specificity and potency against ALDH1A3.
- This filing established Theranib’s position as a pioneer in developing ALDH1A3 inhibitors for targeted cancer therapy.
Strategic Transition to PCT (2024):
- Converted the original patent into an International Patent Cooperation Treaty (PCT) application, extending protection to multiple jurisdictions worldwide.
- Initiated the US utility patent filing to secure rights in one of the largest oncology markets globally.
- Conducted freedom-to-operate (FTO) analysis to confirm the absence of conflicts with existing patents, ensuring exclusivity for VE3.

Secured robust intellectual property (IP) protection for VE3, covering:
- The compound’s structure.
- Its mechanism of action targeting ALDH1A3.
- Applications in cancer therapy, particularly in chemotherapy-resistant and metastatic cancers.
Enhanced the company’s valuation, positioning Theranib as an attractive investment opportunity for venture capital and pharmaceutical partnerships.

Designed a patent strategy to maximize geographic and market coverage, focusing on regions with high oncology drug demand (e.g., USA, EU5, Japan).
Continued to generate supporting data from preclinical studies to strengthen the patent’s claims and ensure its enforceability during future commercialization stages.
Built a legal framework to defend IP rights against competitors in the oncology space.

Established a competitive moat around Theranib’s innovative approach to ALDH1A3 inhibition, providing a foundation for future research and clinical development.
Enhanced credibility with investors and regulatory agencies by demonstrating a proactive approach to safeguarding innovation.